Recent developments in the discovery of selective glucocorticoid receptor modulators (SGRMs).
Steroidal glucocorticoids are widely prescribed for the treatment of a variety of inflammatory and autoimmune diseases. Although they are effective, the side-effects associated with chronic glucocorticoid treatment, such as osteoporosis and hyperglycemia, can severely limit their long-term use. Hence, there is a need to develop new effective anti-inflammatory agents for systemic use which are dissociated from their unwanted side effects.
Discovery Research, Ligand Pharmaceuticals, 10275 Science Center Drive, San Diego, CA 92121, USA.
Andrew R
AR
Hudson
Steven L
SL
Roach
Robert I
RI
Higuchi
D000893:Anti-Inflammatory Agents / Q000737:chemistry*; D015195:Drug Design; D005938:Glucocorticoids / Q000737:chemistry; D006801:Humans; D008024:Ligands; D011965:Receptors, Glucocorticoid / Q000187:drug effects*; D013329:Structure-Activity Relationship
D000893:Anti-Inflammatory Agents; D005938:Glucocorticoids; D008024:Ligands; D011965:Receptors, Glucocorticoid